TransMedics Group Inc vs United Microelectronics Corp — how do they compare? TransMedics Group Inc trades at $77.33 (market cap $2.74B), while United Microelectronics Corp trades at $22.94 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 21.2× TransMedics Group Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and United Microelectronics Corp for 42 Days on average.
| TMDX | UMC | |
|---|---|---|
Market Cap | $2.74B | $58.02B |
Volume | 949,331 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $150.42 | $28.02 |
52-Week Low | $61.99 | $7.02 |
Typical Hold Time | 24 Days | 42 Days |
Enterprise Value | $3.13B | $55.10B |
Dividend Yield | — | 1.76% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
UMC trades at $22.92, down 1.67% on the day, with a bullish technical signal despite recent weakness. The company has delivered strong earnings beats in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue is projected to grow to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow trends show a positive turnaround with 2025 net cash flow of $5.66 billion after two years of negative flows.
The outlook remains positive with strong profitability metrics and analyst upgrades, though competition and market volatility present risks. The stock appears fundamentally sound with improving cash generation and earnings momentum, supported by AI-driven semiconductor demand. Valuation metrics suggest reasonable pricing relative to growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →